Multidrug resistant gram-negative bacteria in solid organ transplant recipients

American Journal of Transplantation

Volumn 9, Issue SUPPL. 4, 2009, Pages

  Van Delden, C ^a   Blumberg, E A ^b  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Achromobacter; Acinetobacter; Burkholderia; ESBL; Pseudomonas; Stenotrophomonas

Indexed keywords

AMINOGLYCOSIDE; AMINOGLYCOSIDE ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CARBAPENEM; CARBAPENEMASE; CEFEPIME; CEFTAZIDIME; CIPROFLOXACIN; COLISTIN; COTRIMOXAZOLE; EXTENDED SPECTRUM BETA LACTAMASE; FOSFOMYCIN; IMIPENEM; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULTAMICILLIN; TIGECYCLINE;

ACHROMOBACTER; ACINETOBACTER; ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL THERAPY; BACTERIAL COLONIZATION; BACTERIUM CULTURE; BURKHOLDERIA; BURKHOLDERIA CEPACIA; DEVICE INFECTION; DRUG MEGADOSE; ENTEROBACTERIACEAE; GRAFT INFECTION; GRAFT RECIPIENT; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; HUMAN; HYGIENE; INCIDENCE; INFECTION PREVENTION; INFECTION RATE; KLEBSIELLA PNEUMONIAE; LUNG GRAFT REJECTION; MULTIDRUG RESISTANCE; MULTIPLE COMBINATION BACTERICIDAL ANTIBIOTIC TESTING; NEPHROTOXICITY; NONHUMAN; ORGAN TRANSPLANTATION; OVERALL SURVIVAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSEUDOMONAS; REVIEW; RISK FACTOR; STENOTROPHOMONAS; TREATMENT CONTRAINDICATION; URINARY TRACT INFECTION;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; DRUG RESISTANCE, MICROBIAL; DRUG RESISTANCE, MULTIPLE; GRAM-NEGATIVE BACTERIA; HUMANS; ORGAN TRANSPLANTATION; RISK FACTORS;

EID: 72949090190     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2009.02890.x     Document Type: Review

References (47)

1. Dowzicky MJ, Park CH. Update on antimicrobial susceptibility rates among gram-negative and gram-positive organisms in the United States: Results from the Tigecycline Evaluation and Surveillance Trial (TEST) 2005 to 2007.
2. The European Antimicrobial Resistance Surveillance System Annual Report. http://www.rivm.nl/earss/Images/EARSS%202007-FINAL-tcm61-55933.pdf
3. Green M, Barbadora K. Recovery of ceftazidime-resistant Klebsiella pneumoniae from pediatric liver and intestinal transplant recipients. Pediatr Transplant 1998 2 : 244 230.
4. Paterson DL, Singh N, Rihs JD et al. Control of an outbreak of infection due to extended-spectrum beta-lactamase-producing Escherichia coli in a liver transplantation unit. Clin Infect Dis 2001 33 : 126 128.
5. Linares L, Cervera C, Cofán F et al. Risk factors for infection with extended-spectrum and AmpC β-lactamase-producing Gram-negative rods in renal transplantation. Am J Transplant 2008 8 : 1000 1005.
6. Rebuck JA, Olsen KM, Fey PD et al. Characterization of an outbreak due to extended-spectrum beta-lactamase-producing Klebsiella pneumoniae in a pediatric intensive care unit transplant population. Clin Infect Dis 2000 31 : 1368 1372.
7. Martins IS, Moreira BM, Riley LW et al. Outbreak of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae infection among renal transplant recipients. J Hosp Infect 2006 64 : 305 308.
8. Zárate MS, Gales AC, Picão RC et al. Outbreak of OXY-2 producing Klebsiella oxytoca in a renal transplant unit. J Clin Microbiol 2008 46 : 2099 2101.
9. Sopirala MD, Pope-Hartman A, Nunley DR et al. Multidrug-resistant Acinetobacter baumanii pneumonia in lung transplant recipients. J Heart Lung Transplant 2008 27 : 804 807.
10. Trottier V, Namias N, Pust DG et al. Outcomes of Acinetobacter baumanii infection in critically ill surgical patients. Surgical Infections 2007 8 : 437 443. (Pubitemid 47493521)
11. Schwaber MJ, Klarfield-Lidji S, Navon-Venezia S et al. Predictors of carbapenem-resistant Klebsiella pneumonia acquisition among hospitalized adults and effect of acquisition on mortality. Antimicrob Agents Chemother 2008 52 : 1028 1033.
12. Botha P, Archer L, Anderson RL et al. Pseudomonas aeruginosa colonization of the allograft after lung transplantation and the risk of bronchiolitis obliterans syndrome. Transplantation 2008 85 : 771 774.
13. Hadjiliadis D, Steele MP, Chaparro C. Survival of lung transplant patients with cystic fibrosis harboring panresistant bacteria other than Burkholderia cepacia, compared with patients harboring sensitive bacteria. J Heart Lung Transplant 2007 26 : 834 838.
14. Dobbin J, Maley M, Harkness J et al. The impact of pan-resistant bacterial pathogens on survival after lung transplantation in cystic fibrosis: results from a single large referral centre. J Hosp Infect 2004 56 : 277 282.
15. Murray S, Charbeneau J, Marshall BC, LiPuma JJ. Impact of Burkholderia infection on lung transplantation in cystic fibrosis. Am J Resp Crit Care Med 2008 178 : 363 371.
16. Boussaud V, Guillemain R, Grenet D et al. Clinical outcome following lung transplantation in patients with cystic fibrosis colonised with Burkholderia cepacia complex: results from two French centres. Thorax 2008 63 : 732 737.
17. Alexander BD, Petzold EW, Reller LB et al. Survival After Lung Transplantation of Cystic Fibrosis Patients infected with Burkholderia cepacia complex. Am J Transplant 2008 8 : 1025 1030.
18. Levine SM. A survey of clinical practice of lung transplantation in North America. Chest 2004 125 : 1224 1238.
19. Meachery G, De Soyza A, Nicholson A et al. Outcomes of lung transplantation for cystic fibrosis in a large UK cohort. Thorax 2008 63 : 725 731.
20. Orens JB, Estenne M, Arcasoy S et al. International guidelines for the selection of lung transplant candidates: 2006 update - A consensus report from the pulmonary scientific council of the International Society for Heart and Lung Transplantation. J Heart Lung Transpl 2006 25 : 745 755.
21. Linares L, Cervera C, Cofán F et al. Epidemiology and outcomes of multiple antibiotic-resistant, bacterial infection in renal transplantation. Transplant Proc 2007 39 : 2222 2224.
22. Singh N, Gayowski T, Rihs JD et al. Evolving trends in multiple-antibiotic-resistant bacteria in liver transplant recipients: a longitudinal study of antimicrobial susceptibility patterns. Liver Transplantation 2001 7 : 22 26.
23. Troillet N, Samore MH, Carmeli Y. Imipenem-resistant Pseudomonas aeruginosa: Risk factors and antibiotic susceptibility patterns. Clin Infect Dis 1997, 25 1094 1098.
24. Boffi EL, Amari E, Chamot E et al. Influence of Previous Exposure to Antibiotic Therapy on the Susceptibility Pattern of Pseudomonas aeruginosa Bacteremic Isolates. Clin Infect Dis 2001 33 : 1859 1864.
25. Reinhardt A, Köhler T, Wood P et al. Development and Persistence of Antimicrobial Resistance in Pseudomonas aeruginosa: a Longitudinal Observation in Mechanically Ventilated Patients. Antimicrobial Agents Chemother 2007 51 : 1341 1350.
26. Steinbach S, Sun L, Jiang RZ et al. Transmissibility of Pseudomonas cepacia infection in clinic patients and lung-transplant recipients with cystic fibrosis. N Engl J Med 1994 331 : 981 987.
27. Saiman L, Siegel J, Cystic Fibrosis Foundation Consensus Conference on Infection Control Participants. Infection control recommendations for patients with cystic fibrosis: Microbiology, important pathogens, and infection control practices to prevent patient to patient transmission. Inf Contr Hosp Epidemiol 2003 24 : S6 S52.
28. Niederman MS, Craven DE et al. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Resp Crit Care Med 2005 171 : 388 416.
29. CLSI. Performance Standards for Antimicrobial Susceptibility Testing; Eighteenth Informational Supplement, M100-S19, 2009.
30. Perez F, Hujer AM, Hujer KM et al. Global challenge of multidrug-resistant Acinetobacter baumanii. Antimicrob Agents Chemo 2007 51 : 3471 3484.
31. Lipuma JJ. Update on the Burkholderia cepacia complex. Curr Opin Pulm Med 2005 6 : 528 533.
32. Aaron SD, Vandemheen KL, Ferris W et al. Combination antibiotic susceptibility testing to treat exacerbations of cystic fibrosis associated with multiresistant bacteria: A randomised, double-blind, controlled clinical trial Lancet. Lancet 2005 366 : 463 471.
33. Sturenburg E, Mack D. Extended-spectrum beta-lactamases: Implications for the clinical microbiology laboratory, therapy, and infection control. J Infection 2003 47 : 273 295.
34. Rice LB, Eckstein EC, DeVente J et al. Ceftazidime resistantKlebsiella pneumoniae isolates recovered at the Cleveland Department of Veterans Affairs Medical Center. Clin Infect Dis 1996 23 : 118 124.
35. Bauldoff GS, Nunley DR, Manzetti JD et al. Use of aerosolized colistin sodium in cystic fibrosis patients awaiting lung transplantation. Transplantation 1997 64 : 748 752.
36. Holzmann D, Speich R, Kaufmann T et al. Effects of sinus surgery in patients with cystic fibrosis after lung transplantation: A 10-year experience. Transplantation 2004 77 : 134 136.
37. Leung MK, Rachakonda L, Weill D et al. Effects of sinus surgery on lung transplantation outcomes in cystic fibrosis. Am J Rhinology 2008 22 : 192 196.
38. Jones RN, Biedenbach DJ, Gales AC. Sustained activity and spectrum of selected extended-spectrum beta-lactams (carbapenems and cefepime) against Enterobacter spp. and ESBL-producing Klebsiella spp.: report from the SENTRY antimicrobial surveillance program (USA, 1997-2000). Int J Antimicrob Agents 2003 21 : 1 7.
39. Munoz-Price LS, Weinstein RA. Current Concepts. Acinetobacter infections. N Engl J Med 2008 358 : 1271 1281.
40. Anthony KB, Fishman NO, Linkin DR et al. Clinical and microbiological outcomes of serious infections with multidrug-resistant gram-negative organisms treated with tigecycline. Clin Infect Dis 2008 46 : 567 570.
41. Kanellopoulou M, Pournaras S, Iglezos H et al. Persistent colonization of nine cystic fibrosis patients with an Achromobacter (Alcaligenes) xylosoxidans clone. Eur J Clin Microbiol Infect Dis 2004 23 : 336 339.
42. Falagas ME, Valkimadi P-E, Huang Y-T et al. Therapeutic options for Stenotrophomonas maltophilia infections beyond co-trimoxazole: A systematic review. J Antimicrob Chemother 2008 62 : 889 894.
43. Chamot E, El Amari EB, Rohner P et al. Effectiveness of combination antimicrobial therapy for Pseudomonas aeruginosa bacteremia. Antimicrob Agents Chemother 2003 47 : 2756 2764.
44. Reese AM, Frei CR, Burgess DS. Pharmacodynamics of intermittent and continuous infusion piperacillin/tazobactam and cefepime against extended-spectrum beta-lactamase-producing organisms. Int J Antimicrob Agents 2005 26 : 114 119.
45. Kim A, Sutherland CA, Kuti JL, Nicolau DP. Optimal dosing of piperacillin-tazobactam for the treatment of Pseudomonas aeruginosa infections: Prolonged or continuous infusion? Pharmacotherapy 2007 27 : 1490 1497.
46. Nicolau DP, McNabb J, Lacy MK et al. Continuous versus intermittent administration of ceftazidime in intensive care unit patients with nosocomial pneumonia. Int J Antimicrob Agents 2001 17 : 497 504. (Pubitemid 32492970)
47. Zavascki AP, Goldani LZ, Li J et al. Polymyxin B for the treatment of multidrug-resistant pathogens: A critical review. J Antimicrob Chemother 2007 60 : 1206 1215.